Hook & thesis
Corcept Therapeutics is no longer a single-product specialty play. Korlym has built a durable revenue base, and relacorilant (Lifyorli) is now commercial, giving the company a true two-franchise profile. That combination matters: steady cash flow from Korlym lets Corcept spend on relacorilant’s rollout and oncology combo studies without urgent dilution, while early relacorilant sales provide a path to durable top-line growth beyond Korlym’s legacy runway.
We think the current pullback is a tactical buying opportunity for a mid-term swing. Q3 results on 11/03/2026 beat expectations, revenue momentum looks solid, and technical indicators show an oversold setup (RSI ~21). Enter around the current price and target a reversion toward prior resistance as commercial momentum and near-term regulatory catalysts play out.
Business overview - why the market should care
Corcept discovers and develops drugs that modulate cortisol’s effects. For years the company relied on Korlym (mifepristone) to treat Cushing’s syndrome and related indications; Korlym remains a cash engine. In 2026 Corcept added relacorilant (marketed as Lifyorli), which received FDA approval in March 2026 and posted $47.6 million in Q2 2026 as the first quarter of commercial availability. Korlym sales in H1 2026 were $373.5 million, up 6.2% year-over-year, showing continuing demand even as the company introduces a second product.
The practical implication: Corcept has moved from a single-product valuation toward a multi-product growth story. Investors who previously worried about end-of-life risk for Korlym now have a company with an established cash-generating product and a nascent but growing second franchise that can expand indications and partnerships, especially in oncology combinations.
What the numbers say
- Q3 2026 results (reported 11/03/2026): earnings of $1.01 per share vs consensus $0.68, a 48.5% beat; revenue $340.47 million, topping estimates by ~3.4%.
- H1 2026 Korlym sales totaled $373.5 million, up 6.2% year-over-year; relacorilant posted $47.6 million in Q2 2026 as the first commercial quarter.
- Capitalization and profitability: market cap roughly $7.04 billion, enterprise value about $6.93 billion; trailing free cash flow for the period shown was $194.6 million, supporting internal investment without immediate dilution.
- Valuation multiples are elevated but not frothy for a specialty pharma with recurring sales: price-to-earnings near ~43x (using the snapshot price and reported EPS), price-to-sales roughly 7.3x, and EV/EBITDA at ~61x. Return on equity ~19.4% and return on assets ~15.7% point to efficient capital use.
Technical backdrop
Price has retreated substantially from a 52-week high of $126.38 to the current $64.34. Short-term moving averages and EMA lines are biased lower (EMA50 ~ $90.98), but momentum indicators show oversold conditions: RSI ~21 and MACD indicating bearish momentum. Short interest is meaningful (recent readings near 9–10 million shares), which both raises the risk of downside pressure and the upside for a squeeze if catalysts surprise on the upside.
Valuation framing
At a market cap near $7.0 billion and free cash flow approaching $195 million in the period shown, Corcept is priced as a growth specialty pharma rather than a pure cash-flow defensive stock. The 7.3x price-to-sales and ~43x P/E reflect expectations that relacorilant will add substantial revenue and margins over the next few years. That expectation is plausible: Korlym’s steady sales plus relacorilant’s initial commercial traction (and potential label expansion for Cushing’s) could push revenue well beyond the current base. But the multiples also imply that investor patience is required—disappointing uptake, an FDA setback, or reimbursement headwinds would compress the multiple quickly.
Catalysts to watch
- Regulatory - an FDA decision on relacorilant’s Cushing’s indication is expected by 12/31/2026; a favorable decision or supportive labeling would materially expand the addressable market.
- Commercial traction - relacorilant sequential quarterly revenue prints above the initial $47.6 million quarter would validate the sales force and formulary access efforts.
- Oncology partnerships - positive combination-study readouts or partnerships for relacorilant in oncology would create a new growth vector and derisk dependence on endocrinology sales.
- Quarterly earnings (next report) - continued beats to revenue and EPS would support multiple expansion from current levels.
Trade plan (actionable)
We structure a mid-term bullish trade that balances reward with defined risk:
| Entry | Target | Stop | Horizon |
|---|---|---|---|
| $64.34 | $95.00 | $56.00 | Mid term (45 trading days) |
Rationale: Entering at $64.34 gives exposure near recent support after a steep pullback. The target of $95 is a technically and fundamentally defendable re-rating objective: it approaches the EMA50/previous congestion zone and allows relacorilant to prove out early uptake and regulatory catalysts. The stop at $56 caps downside to a manageable level (~13% below entry). The recommended horizon is mid term (45 trading days) to allow for one or two quarterly data points or regulatory updates to begin resolving uncertainty.
If you prefer a layered approach, consider scaling in half at $64 and adding on confirmation of relacorilant sequential growth or a supportive regulatory update. Tight traders who want a shorter look can use the same entry but a shorter stop and target for a short-term (10 trading days) approach, while longer-term investors should weigh durability of relacorilant sales and potential label or partnership outcomes over a long-term (180 trading days) window.
Risks & counterarguments
- Regulatory risk: The FDA decision on relacorilant’s full label or Cushing’s indication by 12/31/2026 could be unfavorable or come with limiting language, which would slow uptake and materially reduce the upside case.
- Commercial execution: Early relacorilant revenue ($47.6 million in the first commercial quarter) is encouraging, but scaling beyond initial adoption requires payor coverage and physician acceptance. Failure to achieve sequential growth would keep the company reliant on Korlym and pressure the stock.
- Valuation sensitivity: Multiples are high for a company in transition (P/S ~7.3x, P/E ~43x). If growth disappoints, multiple compression could drive significant downside even with solid underlying sales.
- Competition and reimbursement: Competitors or new treatment modalities could erode pricing or market share. Reimbursement decisions are often the key gating factor for specialty endocrinology drugs, and adverse coverage rulings would hurt revenue trajectory.
- Short-interest dynamics: Meaningful short interest can amplify moves both down and up; large intraday swings are possible and could trigger volatility that hurts disciplined stop placement.
Counterargument: The bear case is straightforward — relacorilant may fail to scale or receive a restrictive label, Korlym could face reimbursement pressure or competition, and the current valuation leaves little room for execution missteps. Those outcomes would justify a materially lower stock price than today.
Conclusion and what would change our view
Our base case is a mid-term buy at $64.34 targeting $95 over roughly 45 trading days. The thesis rests on two pillars: Korlym’s continuing cash generation and relacorilant’s early commercial traction plus upcoming regulatory/readout catalysts. If relacorilant posts clear sequential growth, or the FDA decision by 12/31/2026 is favorable, we would increase conviction and consider a higher target. Conversely, if relacorilant disappoints on uptake, the FDA stance is unfavorable, or next-quarter revenue misses and margins deteriorate, we would cut risk exposure and reassess the valuation — that outcome would change our view from buy to neutral or sell.
Trade idea summary: Long CORT at $64.34 with a stop at $56.00 and a target at $95.00 over a mid-term (45 trading days) horizon. Manage position size to account for execution and regulatory risk; use the stop rigorously.
Key data points cited
- Q3 2026 EPS $1.01 vs $0.68 est (reported 11/03/2026)
- Q3 2026 revenue $340.47 million
- H1 2026 Korlym sales $373.5 million; relacorilant $47.6 million in Q2 2026
- Market cap ~ $7.04 billion; EV ~ $6.93 billion; free cash flow ~$194.6 million
- Technical: RSI ~21, 52-week range $28.66 - $126.38